<DOC>
	<DOCNO>NCT02592876</DOCNO>
	<brief_summary>The purpose randomize , open-label study evaluate safety efficacy denintuzumab mafodotin plus RICE ( rituximab , ifosfamide , carboplatin , etoposide ) compare RICE alone treatment patient relapse refractory diffuse large B-cell lymphoma ( DLBCL ) Grade 3b follicular lymphoma . Eligible patient must also candidate autologous stem cell transplant . Patients randomly assign 1:1 ratio receive 3 cycle study treatment either denintuzumab mafodotin + RICE RICE alone . The study ass whether difference 2 group side effect report number patient achieve complete remission end study treatment .</brief_summary>
	<brief_title>Treatment Study Denintuzumab Mafodotin ( SGN-CD19A ) Plus RICE Versus RICE Alone Diffuse Large B-Cell Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Pathologically confirm diagnosis CD20positive relapse refractory diffuse large Bcell lymphoma ( DLBCL ; include de novo transformed DLBCL ) Grade 3b follicular lymphoma Available representative tissue recent biopsy last therapy ; tissue available , fresh biopsy must obtain Received frontline CD20directed immunotherapy anthracycline anthracenedionebased multiagent chemotherapy . Monotherapy rituximab CD20directed immunotherapy maintenance therapy prior frontline chemotherapy , radiotherapy limit field part frontline treatment plan permit . Considered eligible highdose chemotherapy follow autologous stem cell transplant ( ASCT ) Fluorodeoxyglucose ( FDG ) avid disease positive emission tomography ( PET ) , measurable disease great 1.5 cm diameter Eastern Cooperative Oncology Group ( ECOG ) performance less equal 2 Adequate kidney hematologic function assess baseline laboratory data Previous history indolent lymphoma treat 1 multiagent chemotherapy regimen previous cancer therapy recurrent DLBCL Grade 3b follicular lymphoma History autologous allogeneic stem cell transplant History another primary invasive cancer , hematologic malignancy , myelodysplastic syndrome remission least 1 year History progressive multifocal leukoencephalopathy ( PML ) Cerebral/meningeal disease relate underlying malignancy definitively treat Known urinary tract obstruction Patients follow ocular condition : corneal disorder , monocular vision ( i.e. , best correct visual acuity great equal 20/200 one eye ) , active ocular disorder require treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Antibodies , Monoclonal</keyword>
	<keyword>Antibody-Drug Conjugate</keyword>
	<keyword>Antigens , CD19</keyword>
	<keyword>Autologous Stem Cell Transplant</keyword>
	<keyword>Drug Therapy</keyword>
	<keyword>Follicular Lymphoma Grade 3b</keyword>
	<keyword>Hematologic Diseases</keyword>
	<keyword>Immune System Diseases</keyword>
	<keyword>Immunoproliferative Disorders</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Lymphatic Diseases</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Lymphoma , B-Cell</keyword>
	<keyword>Lymphoma , Large B-Cell , Diffuse</keyword>
	<keyword>Lymphoma , Non-Hodgkin</keyword>
	<keyword>Monomethylauristatin F</keyword>
	<keyword>Neoplasms</keyword>
	<keyword>Neoplasms Histologic Type</keyword>
	<keyword>Transformed Lymphoma / DLBCL</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Ifosfamide</keyword>
	<keyword>Carboplatin</keyword>
	<keyword>Etoposide</keyword>
</DOC>